Stay updated on Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial page.

Latest updates to the Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRevision: v3.5.0 updated from the previous v3.4.3.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2.SummaryDifference0.1%

- Check38 days agoChange DetectedNo additions or deletions to core study information were observed; the page content remains unchanged aside from minor UI/metadata adjustments.SummaryDifference0.1%

- Check52 days agoChange DetectedFallopian tube cancer term added and a link to the Genetic and Rare Diseases Information Center added under resources. Page revision updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now displays a revision update from v3.4.0 to v3.4.1, which is a minor change that does not modify the study details or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check74 days agoChange DetectedThe changes are minor UI and versioning updates: addition of Show glossary and Hide glossary options, and label wording updates (Last Update Submitted that Met QC Criteria, No FEAR Act Data) plus the revision tag to v3.4.0. These updates do not modify the study content or how the page functions.SummaryDifference0.4%

Stay in the know with updates to Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial page.